These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23662324)

  • 1. Drug policy: let's maintain pressure on regulatory authorities.
    Prescrire Int; 2013 Apr; 22(137):107. PubMed ID: 23662324
    [No Abstract]   [Full Text] [Related]  

  • 2. Policy Currents.
    Rankin P
    Consult Pharm; 2016 Nov; 31(11):664. PubMed ID: 28107123
    [No Abstract]   [Full Text] [Related]  

  • 3. Towards good governance in drug policy: evidence, stakeholders and politics.
    MacGregor S; Singleton N; Trautmann F
    Int J Drug Policy; 2014 Sep; 25(5):931-4. PubMed ID: 25086908
    [No Abstract]   [Full Text] [Related]  

  • 4. Measuring research influence on drug policy: a case example of two epidemiological monitoring systems.
    Ritter A; Lancaster K
    Int J Drug Policy; 2013 Jan; 24(1):30-7. PubMed ID: 22503108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lethal drug abuse act fails this session.
    Hosp Outlook; 1998 Oct; 1(9):1-2. PubMed ID: 10187189
    [No Abstract]   [Full Text] [Related]  

  • 6. Why a governance perspective could contribute to improving drug policy and engaging the international development community: lessons from Colombia.
    Schultze-Kraft M
    Int J Drug Policy; 2014 Sep; 25(5):1038-9. PubMed ID: 24433814
    [No Abstract]   [Full Text] [Related]  

  • 7. What would an evidence based drug policy be like?
    Singleton N; Strang J
    BMJ; 2014 Dec; 349():g7493. PubMed ID: 25492041
    [No Abstract]   [Full Text] [Related]  

  • 8. Partnerships and communities in English drug policy: the challenge of deprivation.
    Macgregor S; Thickett A
    Int J Drug Policy; 2011 Nov; 22(6):478-90. PubMed ID: 21890338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do drug policy makers access research evidence?
    Ritter A
    Int J Drug Policy; 2009 Jan; 20(1):70-5. PubMed ID: 18226519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy.
    Gilson AM; Maurer MA; Ryan KM; Skemp-Brown M; Husain A; Cleary JF
    J Pain Palliat Care Pharmacother; 2011; 25(3):246-51. PubMed ID: 21882978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ignoring evidence has led to ineffective drug policies, shows research.
    Mooney H
    BMJ; 2012 Jan; 344():e148. PubMed ID: 22228721
    [No Abstract]   [Full Text] [Related]  

  • 12. Public policy statement on national drug policy. American Society of Addiction Medicine.
    J Addict Dis; 1994; 13(4):231-4. PubMed ID: 7734471
    [No Abstract]   [Full Text] [Related]  

  • 13. Harm reduction is now the mainstream global drug policy.
    Wodak A
    Addiction; 2009 Mar; 104(3):343-5; discussion 345-6. PubMed ID: 19207340
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug policy and global regulatory capitalism: the case of new psychoactive substances (NPS).
    Seddon T
    Int J Drug Policy; 2014 Sep; 25(5):1019-24. PubMed ID: 24768473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making drug policy together: reflections on evidence, engagement and participation.
    Roberts M
    Int J Drug Policy; 2014 Sep; 25(5):952-6. PubMed ID: 24882708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dispensaries: the Wild West of Vancouver.
    Lough S
    CMAJ; 2015 Aug; 187(11):E345-E346. PubMed ID: 26195580
    [No Abstract]   [Full Text] [Related]  

  • 17. Balance, change, and responsible prescribing: clinicians need updated regulatory policies and the tools to evaluate patients and meet clinical and regulatory obligations!
    Bolen J
    Clin J Pain; 2010 Jan; 26(1):78-9. PubMed ID: 20026958
    [No Abstract]   [Full Text] [Related]  

  • 18. Governing through problems: the formulation of policy on amphetamine-type stimulants (ATS) in Australia.
    Fraser S; Moore D
    Int J Drug Policy; 2011 Nov; 22(6):498-506. PubMed ID: 22054738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supply reduction's hidden casualties: a view from the trenches.
    Strathdee SA; Patterson TL
    Addiction; 2009 Mar; 104(3):340-1; discussion 345-6. PubMed ID: 19207337
    [No Abstract]   [Full Text] [Related]  

  • 20. The physician as a servant of public policy.
    Stimmel B
    Mt Sinai J Med; 1991 Oct; 58(5):433-6; discussion 437-42. PubMed ID: 1753983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.